research Comparison of Azelaic Acid and Anthralin for the Therapy of Patchy Alopecia Areata
Azelaic acid and anthralin are similarly effective for treating patchy hair loss.
Search
for
Sort by
Research
810-840 / 1000+ results research ERRATUM
research In vitro hair growth-promoting effects of araliadiol via the p38/PPAR-γ signaling pathway in human hair follicle stem cells and dermal papilla cells
Araliadiol may promote hair growth like minoxidil without being toxic.
research This Month in JAAD: October 2021
Oral baricitinib is effective and safe for treating alopecia areata.
research Polymer conjugated retinoids for controlled transdermal delivery
A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with fewer side effects.
research Similar Risk of Sexual Dysfunction in Androgenetic Alopecia Patients Treated With Dutasteride vs. Finasteride: A Retrospective Cohort Database Study
research LB1154 Rising antimicrobial resistance in chronic wounds
DACC-based dressings are more effective than silver-based ones for treating chronic wounds with antimicrobial resistance.
research 5α-Reductase inhibitors in men aged 50 years or older with androgenetic alopecia: A retrospective study
5ARI treatment improves hair growth in older men with minimal side effects.
research P79: Efficacy of baricitinib in adults with alopecia areata: patients’ perspectives on hair regrowth from two phase III randomized controlled trials (BRAVE‐AA1 and BRAVE‐AA2)
Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.
research Evaluation of Serum Ferritin, Creatinine and Liver Enzymes in Patients with ß- thalassemia After Administration of Deferasirox
Deferasirox effectively reduces iron overload in ß-thalassemia patients but may cause some manageable side effects.
research Treatment of moderate-to-severe alopecia areata in patients over the age of 65 with baricitinib
Baricitinib helps treat severe hair loss in people over 65.
research Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
Baricitinib is generally safe for long-term use in treating severe alopecia areata.
research Anthralin/dithranol in dermatology
Anthralin is effective for psoriasis and alopecia with minimal systemic side effects but can irritate the skin.
research Fine mapping of the human AR/EDA2R locus in androgenetic alopecia
Genetic marker rs12558842 strongly linked to male hair loss.
research Safety and efficacy of ALRV5XR in men with androgenetic alopecia: A randomised, double-blinded, placebo-controlled clinical trial
ALRV5XR effectively increases hair density in men with androgenetic alopecia without adverse effects.
research Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.
research Safety and Tolerability of the Dual 5-Alpha Reductase Inhibitor Dutasteride in the Treatment of Androgenetic Alopecia
Dutasteride is safe and effective for treating hair loss, but may decrease libido.
research Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia
Finasteride and dutasteride are effective in treating male hair loss but can cause sexual side effects and birth defects.
research Assessment of Vitamin D Level in Patients of Alopecia Areata
Low vitamin D levels are common in people with Alopecia Areata.
research 15640 Effectiveness and safety of oral dutasteride for male androgenetic alopecia in real clinical practice: A descriptive unicenter study
Low input with cover crop optimizes yield and reduces greenhouse gas emissions.
research Farmácia Barreiros, Porto e Serviços Farmacêuticos do Hospital das Forças Armadas - Polo Porto, Porto
research A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes
Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.
research sQuiz your knowledge: Polycyclic annular plaques on the trunk following dutasteride treatment
Dutasteride for hair loss can cause skin reactions like itchy red plaques.
research Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2
Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research Un asentamiento de la primera Edad del Hierro en el término de Raposal (Arnedo, La Rioja)
The early Iron Age settlement at Raposal shows diverse cultural influences and challenges previous ideas about settlement types in the Ebro Valley.
research 43696 Early real-world experience with baricitinib in the treatment of severe alopecia areata
Baricitinib shows promise in treating severe hair loss.
research 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss
Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
research Baricitinib (Olumiant)
Olumiant should be covered for severe alopecia areata if certain conditions are met.
research Use of 5-Alpha Reductase Inhibitors in Dermatology: A Narrative Review
5-Alpha Reductase Inhibitors are effective for male hair loss and some skin conditions, but their effectiveness in women and safety concerns require careful use.